Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04857957 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability & Pharmacokinetics Study of CNTX-6016 in Healthy Subjects and Subjects With PDN
A Phase 1 study, sponsored by Centrexion Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT04857957 is a Phase 1 study that has completed, run by Centrexion Therapeutics. The registered enrollment target is 46 participants.
The verdict
NCT04857957, a Phase 1 study, has completed, sponsored by Centrexion Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
A Phase 1b study to evaluate the safety, tolerability and pharmacokinetics of multiple ascending doses of CNTX-6016 in healthy subjects and a single cohort to evaluate painful diabetic neuropathy.
Interventions
- DRUG Oral dose CNTX-6016 or oral dose Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2021-04-14 |
| Est. Completion | 2023-08-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04857957
The ClinicalTrials.gov registry entry for NCT04857957 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Centrexion Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Oral dose CNTX-6016 or oral dose Placebo is the first listed.
NCT04857957 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04857957 about?
NCT04857957 is a clinical study titled "Safety, Tolerability & Pharmacokinetics Study of CNTX-6016 in Healthy Subjects and Subjects With PDN". A Phase 1b study to evaluate the safety, tolerability and pharmacokinetics of multiple ascending doses of CNTX-6016 in healthy subjects and a single cohort to evaluate painful diabetic neuropathy.
What is the current status of trial NCT04857957?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2021-04-14. Estimated completion is 2023-08-30.
What interventions are being tested in trial NCT04857957?
The interventions under investigation include: Oral dose CNTX-6016 or oral dose Placebo (DRUG).
Who is sponsoring clinical trial NCT04857957?
This trial is sponsored by Centrexion Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.